NYSE - Delayed Quote • USD
GSK plc (GSK)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:49 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
30,328,000.00
30,328,000.00
29,324,000.00
24,696,000.00
24,354,000.00
Cost of Revenue
8,565,000.00
8,565,000.00
9,554,000.00
8,163,000.00
7,929,000.00
Gross Profit
21,763,000.00
21,763,000.00
19,770,000.00
16,533,000.00
16,425,000.00
Operating Expense
14,418,000.00
14,418,000.00
13,041,000.00
11,655,000.00
11,847,000.00
Operating Income
7,345,000.00
7,345,000.00
6,729,000.00
4,878,000.00
4,578,000.00
Net Non Operating Interest Income Expense
-735,000.00
-735,000.00
-826,000.00
-755,000.00
-852,000.00
Pretax Income
6,064,000.00
6,064,000.00
5,628,000.00
3,599,000.00
5,170,000.00
Tax Provision
756,000.00
756,000.00
707,000.00
83,000.00
67,000.00
Net Income Common Stockholders
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Diluted NI Available to Com Stockholders
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Basic EPS
2.43
2.43
7.43
2.19
2.89
Diluted EPS
2.40
2.40
7.32
2.16
2.85
Basic Average Shares
2,026,000.00
2,026,000.00
2,013,000.00
2,001,500.00
1,990,400.00
Diluted Average Shares
2,055,500.00
2,055,500.00
2,042,000.00
2,026,000.00
2,015,200.00
Total Operating Income as Reported
6,745,000.00
6,745,000.00
6,433,000.00
4,357,000.00
5,979,000.00
Rent Expense Supplemental
27,000.00
27,000.00
17,000.00
20,000.00
27,000.00
Total Expenses
22,983,000.00
22,983,000.00
22,595,000.00
19,818,000.00
19,776,000.00
Net Income from Continuing & Discontinued Operation
4,928,000.00
4,928,000.00
14,956,000.00
4,385,000.00
5,749,000.00
Normalized Income
5,401,553.43
5,401,553.43
4,494,705.22
3,349,189.00
3,071,343.00
Interest Income
48,000.00
48,000.00
31,000.00
11,000.00
17,000.00
Interest Expense
725,000.00
725,000.00
826,000.00
764,000.00
847,000.00
Net Interest Income
-735,000.00
-735,000.00
-826,000.00
-755,000.00
-852,000.00
EBIT
6,789,000.00
6,789,000.00
6,454,000.00
4,363,000.00
6,017,000.00
EBITDA
9,083,000.00
9,083,000.00
8,601,000.00
6,485,000.00
8,067,000.00
Reconciled Cost of Revenue
8,565,000.00
8,565,000.00
9,554,000.00
8,163,000.00
7,929,000.00
Reconciled Depreciation
2,294,000.00
2,294,000.00
2,147,000.00
2,122,000.00
2,050,000.00
Net Income from Continuing Operation Net Minority Interest
4,928,000.00
4,928,000.00
4,256,000.00
2,805,000.00
4,464,000.00
Total Unusual Items Excluding Goodwill
-541,000.00
-541,000.00
-273,000.00
-557,000.00
1,411,000.00
Total Unusual Items
-541,000.00
-541,000.00
-273,000.00
-557,000.00
1,411,000.00
Normalized EBITDA
9,624,000.00
9,624,000.00
8,874,000.00
7,042,000.00
6,656,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-67,446.57
-67,446.57
-34,294.78
-12,811.00
18,343.00
12/31/2020 - 3/28/1980
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SNY Sanofi
49.13
-0.47%
AZN AstraZeneca PLC
75.17
+0.19%
NVS Novartis AG
97.44
-1.64%
BMY Bristol-Myers Squibb Company
44.85
+0.34%
OGN Organon & Co.
18.55
+0.71%
GILD Gilead Sciences, Inc.
65.42
+0.23%
AMGN Amgen Inc.
269.98
+0.22%
MRK Merck & Co., Inc.
131.20
+0.37%
ABBV AbbVie Inc.
159.62
-4.58%
RHHBY Roche Holding AG
30.25
+0.77%